Stanford Pathology Research Centers
U19 Center: A vaccine design to induce protective B and T cell immunity against hepatitis C Virus
(U19P) Steven Foung, MD
The CDC estimates that 3 million people are living with hepatitis C virus (HCV) infection in the United States and there is an annual infection rate of 34,000 new infections. A contributing factor is the consequence of an opioid epidemic that shows no signs of slowing down and is unfortunately associated with increased injection drug use as a major mode to consume illicit opioids. HCV is transmitted by mainly contaminated blood. Data from some states in areas struggling with this problem showed an astonishing 364% increase in infection amongst young adults. The U19 Program is to develop an HCV vaccine to prevent disease progression after virus exposure in a vaccinated individual. The projects focus on the development of a vaccine that will elicit broadly protective antibodies and cellular responses that are long-lasting.
Stanford Impact of Genomic Variation on Function Center
(SIGVFC) Ansuman Satpathy, MD, PhD
A comprehensive map of gene expression and gene regulation in human cells is critical to understand how genetic variation impacts human health and disease. Since gene regulation can be exquisitely cell type-, tissue-, and disease-specific, a comprehensive catalog of these elements has been limited by the lack of scalable single-cell methods that can be applied to diverse human tissues. The mission of the Stanford Impact of Genomic Variation on Function Center is to create a high-quality, open-access, and single cell-resolution reference map of human gene expression and regulation in immune cells during human development, across organ systems in healthy adults, and in patient tissues from diverse immune-related diseases.
The Stanford Impact of Genomic Variation on Function Center is part of a consortium: Impact-of-Genomic-Variation-on-Function-Consortium
Stanford U54 SARS-CoV-2 Serological Sciences Center of Excellence
(SUSS-COE) Scott Boyd, MD, PhD
We propose the Stanford U54 SARS-CoV-2 Serological Sciences Center of Excellence (SUSS-COE) as a member of the SeroNet consortium gathered to address the urgent need for better understanding of human immune responses to the SARS-CoV-2 coronavirus pandemic that has engulfed the U.S. and the world. We will emphasize deep mechanistic analysis of the adaptive immune responses of COVID-19 patients, spanning serological, B cell and T cell responses; analysis of immune responses in the blood as well as mucosal tissue sites; comparing immune responses induced by infection to those induced by candidate vaccines; and paying particular attention to the understanding the clinical needs and immune responses of underserved, underrepresented and at-risk patient populations. Within these parameters, we will attempt to determine the factors that result in effective and durable immunity to SARS-CoV-2 infection and provide useful knowledge and tools for physicians and patients.
The Stanford U54 SARS-CoV-2 Serological Sciences Center of Excellence is part of a consortium. For more information about SeroNet please go to: https://med.stanford.edu/stanfordseronet
Stanford Mendelian Genomics Research Center
(U01 HG011762-01) Stephen Montgomery, MD, PhD
Rapid advances in genomics have ushered in new opportunities for Mendelian disease discovery and diagnosis. In the last decade, exome and genome sequencing have moved from the research domain to clinical practice. These approaches have identified new disease genes and causative variants for ~30% of individuals suffering from a rare genetic disease. We believe that the systematic application of promising new genomics assays coupled with innovative computational approaches will foster discovery benefitting the 70% of symptomatic individuals without a genetic diagnosis. To this end we are applying long-read whole genome sequencing, RNA-sequencing, epigenomics assays, metabolomics and targeted in vitro and in vivo assays to evaluate a cohort of undiagnosed individuals suspected to have a Mendelian disorder. Our approach is augmented through the development and application of computational strategies enabling improved gene and phenotype matching, integrative multi-omics analysis, and variant interpretation. This work is expected to establish a new frontier in Mendelian disease discovery.
The Stanford Mendelian Genomics Research Center (MRGC) team has developed key prior expertise and leadership in the use of diverse state-of-the-art experimental and computational methods for the diagnosis and discovery of Mendelian disorders. We hypothesize that the next phase of Mendelian genomics research will be defined by assessing and deploying the most effective ‘omics’ strategies. We have proposed that ongoing and iterative integration of functional genomics data into the translational genomics toolkit will significantly increase discovery of new gene and variant disease associations beyond the capabilities of DNA-sequencing assays alone. Work at our site will potentiate the broad impact of the MGRC sites across the country by providing a platform for functional genomics research, validation and diagnosis in Mendelian disease.